Single B cell technology comprises a group of methods used to isolate, characterize, and recover antibody sequences from individual B lymphocytes or antibody-secreting cells. In antibody discovery, these workflows connect the phenotype of a single cell, such as antigen binding or antibody secretion, to the immunoglobulin heavy- and light-chain sequences responsible for that activity.
A typical workflow begins with B cells obtained from immunized animals, infected or vaccinated human donors, or other biologically relevant samples. Antigen-specific B cells or antibody-secreting cells are then enriched or isolated using fluorescence-activated cell sorting, microfluidic compartmentalization, microwell systems, or related single-cell methods. Immunoglobulin variable-region genes are subsequently amplified, sequenced, cloned, and expressed as recombinant monoclonal antibodies for confirmatory characterization.
This approach differs fundamentally from hybridoma technology. Hybridoma generation requires fusion of primary B cells with immortal myeloma cells, followed by selection, clonal expansion, and repeated screening. Although hybridoma technology remains an established and productive discovery method, cell fusion is inefficient, and the resulting workflow can be labor-intensive and prolonged. Single B cell methods bypass immortalization and recover antibody sequences directly from selected primary cells, which can substantially reduce the time between sample collection and recombinant antibody evaluation.
The importance of single B cell technology extends beyond speed. By interrogating immune repertoires at single-cell resolution, researchers can identify rare antigen-reactive clones, preserve naturally occurring immunoglobulin chain combinations, and examine antibody sequence diversity without first establishing stable cell lines. These capabilities have made single B cell screening an increasingly important component of therapeutic antibody discovery.
Early single B cell workflows depended heavily on manual cell manipulation and low-throughput plate-based assays. Individual cells were deposited into multiwell plates, often by limiting dilution, micromanipulation, or basic cell sorting. Secreted antibodies could then be assessed using enzyme-linked immunosorbent assays, while immunoglobulin genes were recovered by single-cell reverse-transcription polymerase chain reaction.
These methods demonstrated that monoclonal antibodies could be obtained without hybridoma formation, but their throughput was limited. Large numbers of wells had to be processed independently, and low-frequency antigen-specific cells could be missed when only a small fraction of the available repertoire was examined.
The introduction of fluorescence-activated cell sorting provided greater precision and scalability. Fluorescent antigen probes, together with markers defining B cell lineage, differentiation state, viability, and immunoglobulin isotype, enabled researchers to isolate individual antigen-binding cells from heterogeneous populations. Multiparametric flow cytometry also improved exclusion of nonspecific cells and allowed the interrogation of phenotypically distinct populations, including memory B cells and plasmablasts.
Sequencing advances further transformed the field. Conventional Sanger sequencing of individually amplified immunoglobulin genes was progressively supplemented by next-generation sequencing and barcoded single-cell methods. These technologies increased the number of recoverable antibody sequences and enabled broader analysis of repertoire diversity, clonal expansion, somatic hypermutation, and lineage relationships.
A critical limitation of bulk repertoire sequencing is that cellular lysis separates heavy- and light-chain transcripts, thereby losing information about their endogenous pairing. Single-cell compartmentalization and molecular barcoding address this problem by retaining the association between immunoglobulin chains originating from the same cell.
Droplet microfluidics is among the most consequential advances in single B cell screening technologies. In these systems, individual cells are encapsulated in picoliter- to nanoliter-scale aqueous droplets surrounded by an immiscible oil phase. Each droplet functions as an independent reaction chamber in which a cell, its secreted antibody, antigen probes, capture reagents, and molecular barcodes can be physically associated.
The small compartment volume allows secreted antibodies to accumulate rapidly to detectable concentrations. Depending on the assay design, droplets can be screened for antigen binding, immunoglobulin secretion, target specificity, or selected functional properties. Fluorescence-positive droplets are then isolated for recovery of the corresponding cell or immunoglobulin sequence.
Microfluidic compartmentalization can process substantially larger cell populations than conventional multiwell screening while reducing reagent consumption. Published systems have demonstrated screening and sorting of rare antibody-secreting cells, including cells representing approximately 0.1% of an input population.
Newer approaches combine microfluidic encapsulation with antibody-capture hydrogels, nanovials, beads, or other structured carriers that retain secreted immunoglobulins near the originating cell. The resulting cell-antibody complexes can be analyzed using conventional flow cytometry, linking high-throughput secretion assays with established fluorescence-activated sorting infrastructure.
Next-generation sequencing has expanded the scale at which antibody repertoires can be evaluated. However, sequence depth alone is insufficient for monoclonal antibody reconstruction if native heavy- and light-chain relationships are not retained.
Single-cell barcoding addresses this limitation by assigning a shared molecular identifier to transcripts derived from the same cell. Heavy- and light-chain variable regions can therefore be computationally paired after sequencing. Alternative methods physically link immunoglobulin transcripts before pooled amplification.
Preserving native pairing is important because antigen recognition is determined by the combined structural contributions of both chains. Artificial reassortment can alter binding specificity, affinity, stability, or expression. Recovery of naturally paired sequences therefore reduces uncertainty during recombinant antibody reconstruction and provides a more faithful representation of the in vivo immune response.
Modern flow cytometry can assess numerous cellular and probe-associated parameters simultaneously. In single B cell discovery, this enables antigen-binding signals to be evaluated alongside markers for cell viability, lineage, maturation state, activation, and immunoglobulin isotype.
The use of differently labeled antigen probes can improve specificity. For example, cells binding two versions of the same antigen conjugated to distinct fluorophores may be prioritized, while cells binding fluorophores, affinity tags, streptavidin, or irrelevant proteins can be excluded. Competitive probes may also help distinguish epitope-specific populations.
Flow cytometry is most directly suited to identifying cells carrying surface-expressed B cell receptors. Plasma cells, by contrast, generally secrete large quantities of immunoglobulin but may display relatively little surface antibody. Microfluidic secretion assays, antibody-capture matrices, or short-term culture methods can therefore complement flow cytometry when antibody-secreting cells are the principal discovery source.
It is also important to distinguish binding-based selection from direct affinity measurement. Fluorescence intensity can help enrich strongly reactive cells, but it may be affected by receptor density, probe labeling, avidity, and assay configuration. Quantitative affinity determination generally requires subsequent analysis of recombinantly expressed antibodies using methods such as surface plasmon resonance or biolayer interferometry.
Automation is improving multiple stages of single B cell antibody discovery, including sample preparation, liquid handling, imaging, clone tracking, sequence annotation, recombinant expression, and assay data management. Standardized automation can reduce variability associated with repetitive manual operations and support more consistent processing of large candidate sets.
Computational methods are also becoming increasingly relevant. Bioinformatic pipelines can identify clonotypes, annotate V(D)J gene usage, assess somatic hypermutation, group sequences into clonal families, and prioritize representatives from highly expanded or diverse lineages. Machine-learning models are being investigated for antigen-specificity classification, developability assessment, structural prediction, and candidate ranking. However, computational predictions require appropriate training data and experimental validation; they do not replace direct confirmation of binding, specificity, function, or manufacturability.
Modern single B cell workflows can shorten antibody discovery timelines by eliminating cell-fusion and stable-hybridoma-generation steps. Antibody sequences may be recovered shortly after antigen-reactive cells are identified, allowing recombinant expression and characterization to begin earlier.
High-throughput screening also increases the probability of detecting rare clones. This is particularly relevant when the desired antibody originates from a small B cell population, recognizes a subdominant epitope, exhibits cross-reactivity across related antigens, or is present only transiently after immunization or infection.
Another major advantage is preservation of natural heavy–light chain pairing. Because both immunoglobulin chains are recovered from the same cell, the recombinant antibody is more likely to reproduce the specificity selected by the immune system. This contrasts with bulk sequencing workflows in which chain relationships must be inferred or reconstructed.
Single-cell approaches can also be valuable when biological material is limited. Human clinical specimens, small-animal samples, fine-needle aspirates, and selected tissue-derived populations may provide relatively few cells. Miniaturized assays and targeted enrichment can extract more information from these constrained samples than workflows requiring extensive cell expansion. Nevertheless, sample requirements vary according to cell frequency, viability, assay sensitivity, and the desired diversity of the resulting panel.
Single B cell technologies are extensively used to isolate neutralizing antibodies from infected, vaccinated, or convalescent donors. Antigen-specific memory B cells and plasmablasts can provide direct access to antibodies generated through a biologically relevant immune response.
These methods have supported research on pathogens including human immunodeficiency virus, influenza virus, Ebola virus, respiratory syncytial virus, and coronaviruses. During the COVID-19 pandemic, rapid isolation and sequencing of SARS-CoV-2-reactive B cells contributed to the identification of neutralizing antibodies on timelines compatible with accelerated therapeutic development.
In oncology, single B cell screening can support the discovery of antibodies against tumor-associated antigens, immune-regulatory receptors, and components of the tumor microenvironment. Depending on the screening design, candidates may be selected for receptor blockade, receptor agonism, cell internalization, immune-cell recruitment, or recognition of antigen-expressing tumor cells.
The recovered sequences can subsequently be incorporated into conventional immunoglobulin G molecules, bispecific antibodies, antibody–drug conjugates, chimeric antigen receptor recognition domains, or other engineered formats. Functional validation remains essential because antigen binding alone does not establish an appropriate mechanism of action.
Single B cell analysis can characterize autoreactive clones and elucidate the antibody repertoires associated with autoimmune disease. Patient-derived B cells may reveal antibodies recognizing self-antigens, modified proteins, immune complexes, or disease-associated receptors.
From a therapeutic perspective, single B cell discovery can also be used to identify antibodies that inhibit inflammatory mediators or modulate immune-cell signaling. In parallel, repertoire analysis can provide mechanistic information about clonal expansion, affinity maturation, and the persistence of disease-associated B cell lineages.
Analysis of antigen-specific B cells can reveal which epitopes are targeted after vaccination and how those responses evolve over time. Broadly reactive or neutralizing antibodies can inform structure-guided antigen design by identifying conserved and functionally vulnerable epitopes.
During an emerging infectious disease outbreak, single B cell methods provide a direct route from donor samples to antibody sequences. When combined with rapid gene synthesis, high-throughput expression, and functional screening, this approach can support both therapeutic antibody discovery and evaluation of vaccine-induced immunity.
Despite substantial progress, single B cell screening remains technically demanding. High-parameter flow cytometers, microfluidic instrumentation, sequencing capabilities, and automated data infrastructure may require considerable capital investment and specialist expertise. Assay development can also be complex because antigen format, labeling strategy, cell phenotype, secretion rate, and screening threshold all influence performance.
Cost remains an important consideration, particularly for laboratories processing relatively few samples. High-throughput platforms can reduce reagent use per cell, but instrument acquisition, custom microfluidic development, sequencing, and downstream recombinant validation may still be resource-intensive.
Future workflows are likely to integrate single-cell screening more closely with synthetic biology and computational antibody engineering. Experimentally recovered antibodies can serve as validated starting points for affinity maturation, specificity optimization, Fc engineering, and multispecific format development. Sequence- and structure-based models may help prioritize variants, but their output must be assessed using appropriately designed biochemical, biophysical, and cellular assays.
The broader objective is not simply to generate more sequences. It is to establish an integrated discovery process that connects native antibody sequence, cellular origin, antigen specificity, functional activity, and developability as efficiently as possible.
Biointron applies droplet-based microfluidics through its AbDrop single B cell screening platform. The workflow can screen up to 2 × 10^6 plasma B cells from immunized animals. Individual antibody-secreting cells are compartmentalized in microdroplets, where secreted antibodies can be assessed for antigen binding. Selected cells are subsequently processed using barcoded next-generation sequencing to recover naturally paired heavy- and light-chain sequences.
Screening millions of antibody-secreting cells increases the opportunity to detect low-frequency antigen-specific clones that could be missed by lower-throughput approaches. Following sequence recovery, selected antibodies can be advanced into recombinant expression and analytical validation, including enzyme-linked immunosorbent assay, surface plasmon resonance, and flow cytometry. Format-appropriate functional assays may also be incorporated according to the intended biological mechanism.
By linking high-throughput single-cell screening with sequencing, recombinant antibody production, and downstream characterization, Biointron provides an integrated workflow designed to support reliable and scalable antibody discovery programs.
What makes single B cell antibody technologies faster than hybridoma technology?
Single B cell workflows recover immunoglobulin genes directly from selected primary cells. They therefore avoid B cell–myeloma fusion, hybridoma selection, stable clone expansion, and multiple rounds of supernatant screening. Recombinant expression can begin after sequence recovery and candidate selection.
How does single B cell technology ensure accurate heavy–light chain pairing?
Individual cells are physically isolated in wells, droplets, or other compartments. Heavy- and light-chain transcripts from each cell are amplified separately within that compartment or labeled with a shared cellular barcode. The sequences can then be assigned to their cell of origin and reconstructed as naturally paired antibodies.
What innovations are driving current advances in screening?
Important developments include droplet microfluidics, antibody-capture particles and hydrogels, high-parameter flow cytometry, single-cell next-generation sequencing, molecular barcoding, automated liquid handling, and computational sequence analysis. Together, these technologies increase throughput and strengthen the connection between cellular phenotype and antibody genotype.
Can single B cell technology detect antibodies against rare antigens?
The technology can identify low-frequency B cell clones when sufficiently large cell populations are screened and the assay uses a sensitive, specific antigen-detection strategy. Success depends on factors including antigen quality, immunization or donor response, cell viability, assay background, and the abundance of relevant cells.
What role does Biointron play in applying these technologies to discovery projects?
Biointron’s AbDrop platform combines microfluidic screening of antibody-secreting cells with antigen-binding selection, barcoded sequencing, native heavy–light chain recovery, recombinant expression, and downstream antibody characterization. The platform is designed to process up to two million plasma B cells, supporting the recovery of rare antigen-reactive candidates from immunized-animal repertoires.
For an antibody candidate, strong target binding is only part of the path toward……
Explore VHH-based biosensors for high-sensitivity detection using nanobodies in ……
Biointron’s Antibodies After Hours: BIO 2026 Reception was held at The Lion's Sh……
Explore how VHH antibodies stabilize protein conformations for crystallography, ……
You can also contact us on the Scientist and Science Exchange marketplaces.
